{"cluster": 45, "subcluster": 9, "abstract_summ": "We hypothesized that low molecular weight heparin (LMWH) may attenuate cytokine storm in COVID-19 patients therefore LMWH could be a valid adjunctive therapeutic drug for the treatment of COVID-19 pneumopathy.This is amplified in critically ill patients.Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.The coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged health care systems and physicians worldwide to attempt to provide the best care to their patients with an evolving understanding of this unique pathogen.BACKGROUND A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, the application of heparin in COVID-19 has been recommended by some expert consensus due to the risk of disseminated intravascular coagulation and venous thromboembolism.", "title_summ": "COVID-19, coagulopathy and venous thromboembolism: more questions than answersAnticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced CoagulopathyThe Role of Anticoagulation in COVID-19-Induced HypercoagulabilityPrevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoringJAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic riskPrevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before GuidelinesCoagulopathy, thromboembolic complications and the use of heparin in COVID-19 PneumoniaCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-upCoagulopathy of Coronavirus Disease 2019Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forumCOVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection.Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis.Anti-Coagulant and Anti-Platelet Therapy in the COVID-19 Patient:", "title_abstract_phrases": "COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-upAbstract Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis.Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.We hypothesized that low molecular weight heparin (LMWH) may attenuate cytokine storm in COVID-19 patients therefore LMWH could be a valid adjunctive therapeutic drug for the treatment of COVID-19 pneumopathy.The coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged health care systems and physicians worldwide to attempt to provide the best care to their patients with an evolving understanding of this unique pathogen.This is amplified in critically ill patients."}